日本小林制药公司近日宣布，有4名消费者在服用该公司生产的含红曲成分的保健品后死亡。这一消息引起了公众的广泛关注。小林制药表示，目前正在配合相关部门进行调查，以确定死亡事件与保健品之间的关联性。
红曲是一种传统的中药成分，被广泛用于降低胆固醇和预防心血管疾病。然而，长期或过量摄入红曲可能会有副作用，包括横纹肌溶解症和肝功能损害等。小林制药的保健品中红曲成分的含量和安全性正受到质疑。
事件发生后，小林制药立即暂停了相关产品的销售，并敦促消费者停止使用该产品。该公司表示，将全力配合调查，并对受害者家属表示深切的同情和慰问。
英文标题：Four Deaths Linked to Kobayashi Pharmaceutical’s Red Yeast Rice Supplements
英文关键词：Kobayashi Pharmaceutical, Red Yeast Rice Supplements, Deaths
英文新闻内容：
Kobayashi Pharmaceutical has announced that four consumers have died after taking its red yeast rice supplements. The announcement has sparked widespread public concern. Kobayashi Pharmaceutical is cooperating with relevant authorities to investigate the connection between the deaths and the supplements.
Red yeast rice is a traditional Chinese medicine ingredient commonly used to lower cholesterol and prevent cardiovascular diseases. However, long-term or excessive intake of red yeast rice may have side effects, including rhabdomyolysis and liver damage. The amount and safety of red yeast rice in Kobayashi Pharmaceutical’s supplements are now being questioned.
Following the incident, Kobayashi Pharmaceutical has halted the sale of the relevant products and urged consumers to stop using them. The company states that it will fully cooperate with the investigation and expresses deep sympathy and condolences to the families of the victims.
【来源】http://www.chinanews.com/gj/2024/03-28/10188697.shtml
Views: 1